Related Experiment Videos
Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies
1Child Neurology Department, Ospedale Maggiore, Bologna, Italy. gobbig@net27.it
Insights
Vigabatrin monotherapy effectively treated childhood partial epilepsies, showing good tolerability. This suggests vigabatrin as a potential alternative first-line treatment for pediatric epilepsy.
Area of Science:
- Neurology
- Pediatric Epilepsy
Background:
- Childhood partial epilepsies require effective first-line treatments.
- Assessing novel monotherapy options is crucial for pediatric epilepsy management.
Purpose of the Study:
- To evaluate the efficacy and tolerability of vigabatrin as a first-line monotherapy for childhood partial epilepsies.
- To compare vigabatrin with carbamazepine in a pilot study.
Main Methods:
- Prospective, open-label, comparative pilot study.
- Two groups: 40 patients on vigabatrin monotherapy, 40 on carbamazepine monotherapy.
- Assessed seizure reduction, EEG abnormalities, and tolerability.
Main Results:
- Vigabatrin showed high efficacy in idiopathic partial epilepsy (82% seizure reduction) and good results in symptomatic cases (50%).
- Vigabatrin significantly reduced interictal EEG abnormalities compared to carbamazepine (P < 0.05).
- Vigabatrin demonstrated good tolerability with minimal irritability; carbamazepine caused sedation in some patients.
Conclusions:
- Vigabatrin monotherapy is effective and well-tolerated for childhood partial epilepsies.
- Vigabatrin presents a viable alternative first-line treatment option for pediatric epilepsy.
- Further randomized trials are recommended to confirm these findings.
Abstract:
This was a prospective open comparative pilot study to assess the efficacy and tolerability of first-line vigabatrin monotherapy in childhood partial epilepsies. Two groups of patients were recruited over the same period. The vigabatrin monotherapy group comprised 40 patients (18 male, 22 female; mean age at last visit 7.5 years); the comparative carbamazepine monotherapy group comprised 40 consecutive clinic patients (22 male, 18 female; mean age at last visit 7.8 years). Seizures disappeared in 82% of vigabatrin patients and in all carbamazepine patients with idiopathic partial epilepsy, and in 50% of vigabatrin patients and 55% of carbamazepine patients with symptomatic partial epilepsy. Interictal EEG abnormalities decreased in vigabatrin patients more than in carbamazepine patients (P < 0.05). Tolerability was good in vigabatrin patients, but four out of 37 showed mild irritability by the end of the trial. Persistent sedation was observed in eight of the 40 patients receiving carbamazepine. No patient had drug therapy discontinued because of side-effects. During vigabatrin long-term monotherapy, efficacy and good clinical tolerability were maintained. These results suggest that vigabatrin may be an alternative first-line treatment for childhood partial epilepsies. Further blinded comparative randomized trials are needed.